STING1 and non-small cell lung carcinoma: Still, a safe, effective, and efficient way of STING‐agonism in advanced‐stage solid tumors, including NSCLC could strongly potentiate PD‐L1 immunotherapies and transform these aggressive malignancies into chronic conditions.